Early bactericidal activity of sitafloxacin against pulmonary tuberculosis

作者：Lihui Nie, Jing Tong, Guihui Wu, Juan Du, Yuanyuan Shang, Yufeng Wang, Zhangjun Wu, Yuanhong Xu, Yi Ren, Youyi Rao, Yu Pang, M Y Gao · 发表于：Microbiology Spectrum · 年份：2024 · DOI：10.1128/spectrum.01645-24 · 被引用次数：5 · 研究领域：Antibiotic Resistance in Bacteria、Pneumonia and Respiratory Infections、Tuberculosis Research and Epidemiology

ABSTRACT Sitafloxacin is a quinolone broad-spectrum antimicrobial agent, and its pharmacologic properties and in vitro data demonstrate that sitafloxacin has a potent killing effect against Mycobacterium tuberculosis , including drug-resistant strains, which is superior to that of other available quinolones. However, its efficacy in patients with primary-sensitive tuberculosis is unclear. This study aims to evaluate the early bactericidal activity (EBA) of sitafloxacin in patients with primary drug-susceptible tuberculosis. In this early bactericidal activity study, 30 patients with primary smear-positive tuberculosis were randomized to the once-daily oral administration of 200 mg sitafloxacin, 500 mg levofloxacin, or 300 mg isoniazid (INH) for 7 days. Sputum for quantitative culture was collected 2 days before the study of drug administration, followed by 16 hours of overnight sputum collected daily for 7 days of monotherapy. Colony-forming units (CFU) of Mycobacterium tuberculosis were counted from the collected overnight sputum on agar plates to calculate the EBA, defined as log 10 CFU/mL sputum/day. The bactericidal activity was measured by measuring the first 2 days (early bactericidal activity 0–2) and the last 5 days (prolonged early bactericidal properties 2–7) of study drug administration. The EBA 0–2 of INH (0.39 ± 0.22 log 10 CFU/mL/day) was higher than that of levofloxacin (0.26 ± 0.27 log10CFU/mL/day) and sitafloxacin (0.22 ± 0.25 log 10 CFU/mL/day), with no stat...